Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 4, 2021updated 05 Feb 2021 9:23am

Supply of COVID-19 vaccines in the UK will be affected after Brexit transition: Poll

The UK economy is dealing with a double blow caused by the coronavirus pandemic and Brexit.

The UK economy is dealing with a double blow caused by the coronavirus pandemic and Brexit.

Verdict has conducted a poll to assess the impact of Brexit on the supply of COVID-19 vaccines to the UK. Analysis of the poll results indicates that the supply of COVID-19 vaccines may be affected after Brexit transition, as opined by a majority 44% of the respondents.

MD_COVID-19 vaccines supply will be affected in the UK after the Brexit transition
A lesser 38% of the respondents voted that Brexit would have no impact on the vaccine supply-chain.

The remaining 18% of the respondents were unsure about how the Brexit transition would impact the vaccine supply to the UK.

The analysis is based on 223 responses received from the readers of Medical Device Network, a Verdict network site, between 07 December 2020 and 18 January 2021.

Brexit impact on COVID-19 vaccines

The UK officially left the European Union (EU) on 31 January 2020, which started the 11-month period of Brexit transition that ended on 31 December 2020.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

The new trade rules would require imports and exports to undergo customs declarations, tariff payments and other validations. Although these processes may not immediately effect vaccine rollout, they may delay the vaccine programme.

The Chief Executive of the National Health Service (NHS), Sir Simon Stevens, has warned that the UK is facing a shortage of  vaccines and any restrictions on vaccines produced in Europe could further complicate the vaccine rollout programme.

Concerns over AstraZeneca’s failure to deliver vaccine doses to the EU member states due to production issues has triggered a new debate. The company worked in close partnership with the Oxford University to develop the COVID-19 vaccine. The EU has even threatened to tighten the controls over vaccine exports that are produced in Europe in retaliation to AstraZeneca’s plans to reduce vaccines exports to EU.


Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy